JP2014520848A - １型プロピオン酸フルチカゾンの調製のための方法 - Google Patents

１型プロピオン酸フルチカゾンの調製のための方法 Download PDF

Info

Publication number
JP2014520848A
JP2014520848A JP2014520224A JP2014520224A JP2014520848A JP 2014520848 A JP2014520848 A JP 2014520848A JP 2014520224 A JP2014520224 A JP 2014520224A JP 2014520224 A JP2014520224 A JP 2014520224A JP 2014520848 A JP2014520848 A JP 2014520848A
Authority
JP
Japan
Prior art keywords
fluticasone propionate
solvent
solution
type
slurry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014520224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520848A5 (enExample
Inventor
タイスハースト，マーティン・デヴィッド
マルツィアーノ，イヴァン
クグロス，エレフテリオス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of JP2014520848A publication Critical patent/JP2014520848A/ja
Publication of JP2014520848A5 publication Critical patent/JP2014520848A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014520224A 2011-07-08 2012-07-06 １型プロピオン酸フルチカゾンの調製のための方法 Pending JP2014520848A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505612P 2011-07-08 2011-07-08
US61/505,612 2011-07-08
PCT/US2012/045660 WO2013009591A1 (en) 2011-07-08 2012-07-06 Process for the preparation of fluticasone propionate form 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016164301A Division JP2017031161A (ja) 2011-07-08 2016-08-25 １型プロピオン酸フルチカゾンの調製のための方法

Publications (2)

Publication Number Publication Date
JP2014520848A true JP2014520848A (ja) 2014-08-25
JP2014520848A5 JP2014520848A5 (enExample) 2014-10-09

Family

ID=47506422

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014520224A Pending JP2014520848A (ja) 2011-07-08 2012-07-06 １型プロピオン酸フルチカゾンの調製のための方法
JP2016164301A Pending JP2017031161A (ja) 2011-07-08 2016-08-25 １型プロピオン酸フルチカゾンの調製のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016164301A Pending JP2017031161A (ja) 2011-07-08 2016-08-25 １型プロピオン酸フルチカゾンの調製のための方法

Country Status (10)

Country Link
US (2) US10370402B2 (enExample)
EP (1) EP2729480A4 (enExample)
JP (2) JP2014520848A (enExample)
KR (3) KR20140048237A (enExample)
CN (2) CN103649104A (enExample)
AU (1) AU2012282936B2 (enExample)
CA (1) CA2840401C (enExample)
MX (2) MX376564B (enExample)
WO (1) WO2013009591A1 (enExample)
ZA (1) ZA201309531B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017031161A (ja) * 2011-07-08 2017-02-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ １型プロピオン酸フルチカゾンの調製のための方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3517541T3 (pl) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Postać polimorficzna propionianu flutykazonu
WO2015118474A1 (en) * 2014-02-07 2015-08-13 Mylan Laboratories Ltd. Process for the purification of fluticasone propionate using a ketone solvent and water as anti-solvent
CN111662353A (zh) * 2019-03-05 2020-09-15 上海谷森医药有限公司 一种糠酸氟替卡松晶型1的制备方法
CA3136619A1 (en) * 2019-04-10 2020-10-15 Eupraxia Pharmaceuticals Inc. Process for making drug crystals of desired size distribution and morphology
CN110759960B (zh) * 2019-10-30 2021-03-23 山东赛托生物科技股份有限公司 一种丙酸氟替卡松的精制方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038811A1 (en) * 1998-12-24 2000-07-06 Glaxo Group Limited Apparatus and process for preparing crystalline particles
WO2001032125A2 (en) * 1999-11-03 2001-05-10 Glaxo Group Limited Apparatus and process for preparing crystalline particles
WO2003061816A1 (en) * 2002-01-22 2003-07-31 Glaxo Group Limited Apparatus and process for preparing crystalline particles
WO2003066653A2 (en) * 2002-02-04 2003-08-14 Glaxo Group Limited Process for the production of fluticasone propionate, in particular of polymorphic form 1
WO2004001369A2 (en) * 2002-06-20 2003-12-31 Sun Pharmaceutical Industries Limited Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1291A (en) 1980-02-15 1985-10-18 Glaxo Group Ltd Androstane 17 beta carbothioates
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0125604D0 (en) * 2001-10-25 2001-12-19 Glaxo Group Ltd Novel process
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
US7314516B2 (en) * 2004-12-29 2008-01-01 Five Star Technologies, Inc. Hydrodynamic cavitation crystallization device and process
WO2013009591A1 (en) * 2011-07-08 2013-01-17 Pfizer Limited Process for the preparation of fluticasone propionate form 1

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038811A1 (en) * 1998-12-24 2000-07-06 Glaxo Group Limited Apparatus and process for preparing crystalline particles
WO2001032125A2 (en) * 1999-11-03 2001-05-10 Glaxo Group Limited Apparatus and process for preparing crystalline particles
WO2003061816A1 (en) * 2002-01-22 2003-07-31 Glaxo Group Limited Apparatus and process for preparing crystalline particles
WO2003066653A2 (en) * 2002-02-04 2003-08-14 Glaxo Group Limited Process for the production of fluticasone propionate, in particular of polymorphic form 1
WO2004001369A2 (en) * 2002-06-20 2003-12-31 Sun Pharmaceutical Industries Limited Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MURNANE D. ET AL., CRYSTAL GROWTH & DESIGN, vol. 8, no. 8, JPN6015032631, 2008, pages 2753 - 64, ISSN: 0003137134 *
STECKEL H. ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 258, JPN6015032629, 2003, pages 65 - 75, ISSN: 0003137133 *
医薬審発第５６８号, JPN7016001044, 1 May 2001 (2001-05-01), ISSN: 0003306184 *
平山令明, 有機化合物結晶作製ハンドブック−原理とノウハウ−, JPN6015026565, 25 July 2008 (2008-07-25), JP, pages 59 - 60, ISSN: 0003306185 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017031161A (ja) * 2011-07-08 2017-02-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ １型プロピオン酸フルチカゾンの調製のための方法

Also Published As

Publication number Publication date
KR20200117056A (ko) 2020-10-13
MX2014000192A (es) 2014-04-25
JP2017031161A (ja) 2017-02-09
ZA201309531B (en) 2014-08-27
US20140141247A1 (en) 2014-05-22
KR102163368B1 (ko) 2020-10-08
WO2013009591A1 (en) 2013-01-17
AU2012282936A1 (en) 2014-01-16
US10370402B2 (en) 2019-08-06
AU2012282936B2 (en) 2016-11-10
KR20190107165A (ko) 2019-09-18
CA2840401A1 (en) 2013-01-17
EP2729480A1 (en) 2014-05-14
CN106977575A (zh) 2017-07-25
MX2020011330A (es) 2020-11-24
US20200024298A1 (en) 2020-01-23
EP2729480A4 (en) 2014-12-31
CA2840401C (en) 2016-05-17
KR20140048237A (ko) 2014-04-23
CN103649104A (zh) 2014-03-19
MX376564B (es) 2025-03-07

Similar Documents

Publication Publication Date Title
JP2017031161A (ja) １型プロピオン酸フルチカゾンの調製のための方法
JP6499187B2 (ja) 支援された粒子径低減方法
JP4331619B2 (ja) 臭化チオトロピウムの結晶性微粒子
US20120046258A1 (en) Novel crystalline pharmaceutical product
EA016580B1 (ru) Соль янтарной кислоты 1-[2-(2-хлор-4-{[(r)-2-гидрокси-2-(8-гидрокси-2-оксо-1,2-дигидрохинолин-5-ил)этиламино]метил}-5-метоксифенилкарбамоил)этил]пиперидин-4-илового эфира бифенил-2-илкарбаминовой кислоты и ее применение для лечения легочных расстройств
KR20200030107A (ko) 무정형 형태의 빌란테롤 트리페나테이트 및 이의 제조방법
TW200418519A (en) Process for preparing crystalline CICLESONIDE with defined particle size
EA030015B1 (ru) НОВЫЕ КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ ГЕМИНАПАДИЗИЛАТА 5-(2-{[6-(2,2-ДИФТОР-2-ФЕНИЛЭТОКСИ)ГЕКСИЛ]АМИНО}-1-(R)-ГИДРОКСИЭТИЛ)-8-ГИДРОКСИХИНОЛИН-2(1H)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
CN104955449A (zh) 用于吸入治疗的多组分结晶颗粒
Pitchayajittipong et al. Engineering of crystalline combination inhalation particles of a long-acting β2-agonist and a corticosteroid
JP7049270B2 (ja) ラクトースと臭化グリコピロニウムの結晶性医薬品共結晶
US20100120737A1 (en) Amorphous ciclesonide
CN119970731A (zh) 一种含有沙美特罗和噻托铵盐组合物的吸入干粉制剂及其制备方法
CN107951893B (zh) 一种糠酸莫米松粉吸入剂组合物
CN107266518B (zh) 一种糠酸莫米松晶型及其制备方法
CN119925617A (zh) 一种用于治疗慢性阻塞性肺病(copd)的药物组合物及其制备方法
CN120585833A (zh) 一种含有福莫特罗和噻托溴铵组合物的吸入干粉制剂及其制备方法
EP2022796A1 (en) Amorphous ciclesonide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160426